Healthcare / Diagnostics & ResearchShenzhen
$9.63
+0.18 (+1.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-146.7M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.8B
P/E
N/A
•EV/EBITDA
21.0x
↑ROE
-0.6%
↓Gross Margin
59.0%
↑Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.6%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
4.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.17B · net income $-35.8M · FCF $-146.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.17B | $2.17B | $2.55B | $2.90B | $3.61B |
| Net Income | $-35.8M | $-35.8M | $126.8M | $312.6M | $708.2M |
| EBITDA | $290.8M | $290.8M | $483.4M | $652.0M | $1.09B |
| EPS | -0.06 | -0.06 | 0.21 | 0.51 | 1.17 |
| Gross Margin | 59.0% | 59.0% | 55.1% | 55.3% | 54.2% |
| Operating Margin | 2.5% | 2.5% | 11.0% | 15.6% | 24.8% |
| Net Margin | -1.7% | -1.7% | 5.0% | 10.8% | 19.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.10 | 0.10 | 0.11 |
| Current Ratio | 3.16 | 3.16 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-146.7M | $-146.7M | $-329.2M | $23.6M | $-144.5M |
| Returns | |||||
| ROE | -0.6% | -0.6% | 2.0% | 4.9% | 11.3% |
| Valuation | |||||
| P/E | — | — | 61.01 | 28.88 | 15.32 |
| EV/EBITDA | 20.97 | 20.97 | 15.98 | 13.59 | 10.02 |
| P/B | 0.93 | 0.93 | 1.21 | 1.41 | 1.72 |
| Growth & Yield | |||||
| Revenue Growth | -14.8% | -14.8% | -12.0% | -19.7% | — |
| EPS Growth | -128.6% | -128.6% | -59.4% | -56.2% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.2%
Start / end P/E
n/dx → n/dx
EPS bridge
0.21 → -0.06
Residual
-19.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.